LONDON--(BUSINESS WIRE)--Technavio, a market research company, has announced their latest report on stem cell therapy for multiple sclerosis for the period 2018-2022. The report entails an in-depth analysis of the pipeline landscape along with the pipeline molecules in different developmental stages. It also lists out the major regulatory authorities in this market.
Stem cell therapy for multiple sclerosis – market insights
Multiple sclerosis leads to adverse effects on the brain and spinal cord. The exact cause leading to such effects is still not determined. Some unidentified environmental factor usually triggers the disease, especially in genetically predisposed individuals. It is considered to be an autoimmune disease, which takes place when an individual’s immune system attacks the healthy cells in the body.
Various distinct patterns have been identified, depending on the course of the disease. They are relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), and progressive relapsing multiple sclerosis (PRMS).
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
RRMS is the most common disease, which is defined by attacks when symptoms relapses, followed by periods of partial or complete recovery. PPMS is defined as the worsening neurologic function from the onset of symptoms without early relapses. SPMS occurs as a transition stage, without a progressive worsening of neurologic function, in patients diagnosed with RRMS. PRMS is a rather uncommon disease type characterized by the distinct attacks of symptoms.
According to a senior analyst at Technavio for oncology, “At present, the therapies for multiple sclerosis are focused on slowing the progression of the disease rather than developing a cure. The management of multiple sclerosis largely depends on symptomatic interventions.”
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Stem cell therapy for multiple sclerosis – segmentation analysis
The stem cell therapy for multiple sclerosis is segmented into the following RoA, including intravenous, intracerebroventricular, and unspecified (parenteral). The unspecified (parenteral) segment held a market share of 60%, followed by intravenous with 30%, and intracerebroventricular with 10%.
The report also consists of companies that are actively involved in the development of stem cell therapy for multiple sclerosis patients. Based on their financial status, the companies are segmented into Tier-1, Tier-2, and Tier-3.
Technavio’s best deals of the month!
Celebrate Earth Day and clean energy with Technavio. Get 30% discount on all Energy reports. Offer valid from 12th March - 18th March.
Get 20% off on all Media and Entertainment Services reports. Offer valid only till the 31st of March.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.